Parkinson's Disease (PD), a neurodegenerative disorder of unknown etiology which afflicts a large number of our elderly, is characterized by a massive loss of midbrain dopaminergic (DA) neurons and some loss of noradrenergic (NA) and serotonergic (5HT) neurons in the locus coreuleus and raphe nuclei, respectively. The goal of the proposed research is to investigate the potential neuroprotective role of synaptic vesicles in monoaminergic neurons. The hypothesis is that synaptic vesicles within various populations of monoaminergic neurons can provide a storage compartment for neurotoxins and thus reduce the amount of free toxin in the cytosol capable of producing damage. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its toxic metabolite 1-methyl-4-phenylpryidinium (MPP+) will be used because they are potent neurotoxins and because MPP+ is an excellent substrate for the synaptic vesicle monoamine transporter. There are marked differences in the susceptibility of rats and mice to MPTP-induced degeneration of DA neurons which is not associated with the amount of MPP+ to which the neurons are exposed. These findings suggest that there may be a much greater intracellular sequestration of MPP+ within DA neurons in rats as compared to mice. This species difference in neurotoxic response will be used to test the hypothesis. In other studies, the role of vesicular sequestration in NA and 5HT neurons and MPTP toxicity will be evaluated. A multidisciplinary approach will be utilized, including in vivo and in vitro studies, neurochemical and immunohistochemical studies.
The specific aims of this project are: 1) to determine if differences in the capacity of vesicles obtained from the neostriata of rats or mice to accumulate MPP+ contribute to the species differences in the sensitivity of dopaminergic neurons to MPTP/MPP+-induced neurotoxicity; 2) to further examine in vivo the degeneration of monoaminergic neurons produced by the administration of MPTP to mice with dysfunctional vesicles; 3) to examine if reserpinization of animals affects MPTP biodistribution of MPP+ accumulation within the brain; 4) to compare dose-response curves for damage produced by intrastriatal infusions of MPP+ in mice and rats treated with or without a vesicular uptake inhibitor. The possibility that vesicles might provide a storage site for exogenous or endogenous neurotoxins is a novel and intriguing concept. This in turn raises the question as to whether defects in vesicular function of monoaminergic neurons might contribute to the neurodegeneration seen in PD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
3R01AG008479-07S2
Application #
6014752
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Project Start
1989-08-01
Project End
2000-07-31
Budget Start
1999-02-01
Budget End
1999-07-31
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Neurology
Type
Schools of Medicine
DUNS #
622146454
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Moy, Lily Y; Wang, Sheng-Ping; Sonsalla, Patricia K (2007) Mitochondrial stress-induced dopamine efflux and neuronal damage by malonate involves the dopamine transporter. J Pharmacol Exp Ther 320:747-56
Liang, Chang-Lin; Nelson, Omar; Yazdani, Umar et al. (2004) Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J Comp Neurol 473:97-106
Alfinito, Peter D; Wang, Sheng-Ping; Manzino, Lawrence et al. (2003) Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 23:10982-7
Chen, Jiang-Fan; Steyn, Salome; Staal, Roland et al. (2002) 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem 277:36040-4
Gluck, M R; Moy, L Y; Jayatilleke, E et al. (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem 79:152-60
Chen, J F; Xu, K; Petzer, J P et al. (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143
Staal, R G; Yang, J M; Hait, W N et al. (2001) Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res 910:116-25
Staal, R G; Sonsalla, P K (2000) Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 293:336-42
German, D C; Liang, C L; Manaye, K F et al. (2000) Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience 101:1063-9
Staal, R G; Hogan, K A; Liang, C L et al. (2000) In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 293:329-35

Showing the most recent 10 out of 22 publications